Caris ChromoSeq
Myeloid malignancies are complex. Genetic testing shouldn’t be.
Using high-coverage Whole-Genome Sequencing (WGS), Caris ChromoSeq™ is designed to replace the genetic testing portion of the diagnostic workflow for myeloid malignancies — complementing your clinical evaluation.
Seeing the whole genome brings diagnostic clarity.
Caris ChromoSeq reports single-nucleotide variants and short insertions and deletions in >70 genes. These short variants are considered detected when present at a variant allele frequency (VAF) ≥ 10%. When tumor fraction ≥ 20%, genome-wide copy number alterations >5Mb in size and 612 predefined structural variants and fusions (inversions, translocations, deletions or duplications) with known relevance to hematological malignancies are reportable.
One Comprehensive Molecular Profiling Test for Hematologic Malignancies
Caris ChromoSeq is intended for the following myeloid malignancies:
- Myelodysplastic Syndromes (MDS)
- Myeloproliferative Neoplasms (MPN)
- Acute Myeloid Leukemia (AML)
- Patients with suspected myeloid malignancies characterized by unexplained cytopenia persisting for more than four months
Key Benefits:
- Replaces fragmented genetic testing workflows such as cytogenetics, FISH and targeted panels with a single assay
- Uses high-coverage WGS (~200x mapped read depth) to detect structural variants, copy number alterations and mutations genome-wide
- Synthesizes multiple test results into one actionable, easy-to-interpret report
- 7-day average turnaround
Discover
More
Caris Assure® is a minimally invasive blood test that utilizes circulating Nucleic Acid Sequencing (cNAS) to analyze cell-free DNA and RNA from plasma, plus genomic DNA and messenger RNA from circulating white blood cells (WBCs), to distinguish somatic tumor, incidental clonal hematopoiesis (CH) and incidental germline variants.
MI Cancer Seek® is the first and only simultaneous Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS)-based assay with FDA-approved CDx indications for molecular profiling of solid tumors. MI Cancer Seek is available for adult and pediatric (ages 1-22) patients.